Numerous immune-related biomarkers are currently approved in the clinical management of mTNBC, such as programmed death-ligand 1 (PD-L1), tumor-infiltrating lymphocytes (TILs), and mismatch repair (MMR) system [8,9,10]. Here, CD274 is linked to neoplasm.